Search

Displaying results 781 - 790 of 10000 in total
  1. Drug

    Leucine

    go.drugbank.com/drugs/DB00149
    ApprovedInvestigationalNutraceutical

    An essential branched-chain amino acid important for hemoglobin formation.

    Mixtures: POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1000 ML, POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1500 ML
  2. Drug

    Vernakalant

    go.drugbank.com/drugs/DB06217
    ApprovedInvestigational

    Intravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA. … It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates.

  3. Target

    Aggrecan core protein

    go.drugbank.com/bio_entities/BE0004104
    TargetHumans

    This proteoglycan is a major component of extracellular matrix of cartilagenous tissues. A major function of this protein is to resist compression in cartilage. It binds avidly to hyaluronic acid via an N-terminal globular region

    Polypeptides: Aggrecan core proteinSynonyms: Cartilage-specific proteoglycan core protein, Chondroitin sulfate proteoglycan core protein 1
  4. Drug

    Zinc citrate

    go.drugbank.com/drugs/DB11154
    ApprovedInvestigational

    It is available as dietary supplements as a treatment of zinc deficiency and source of zinc, which is an essential trace element.

    Mixtures: Collag-EN, EC + Complex
  5. Drug

    Phenylalanine

    go.drugbank.com/drugs/DB00120
    ApprovedInvestigationalNutraceutical

    Phenylalanine is an essential aromatic amino acid that is a precursor of melanin, [dopamine], [noradrenalin] (norepinephrine), and [thyroxine].

    Mixtures: POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1000 ML, POLİNUTHREE EN-550 ELEKTROLİTLİ AMİNOASİT ÇÖZELTİSİ, GLUKOZ ÇÖZELTİSİ, VE LİPİD EMÜLSİYONU, 1500 ML
  6. Drug

    Ketoconazole

    go.drugbank.com/drugs/DB01026
    ApprovedInvestigational

    [A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. … Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.

  7. Target

    2-oxoglutarate dehydrogenase complex component E1

    go.drugbank.com/bio_entities/BE0000162
    TargetHumans

    2-oxoglutarate dehydrogenase (E1o) component of the 2-oxoglutarate dehydrogenase complex (OGDHC) (PubMed:24495017, PubMed:25210035, PubMed:28435050). … A fraction of the 2-oxoglutarate dehydrogenase complex also localizes in the nucleus and is required for lysine succinylation of histones: associates with KAT2A on chromatin and provides succinyl-CoA to

    Polypeptides: 2-oxoglutarate dehydrogenase complex component E1
  8. Target

    Cytochrome b6-f complex subunit 4

    go.drugbank.com/bio_entities/BE0002473
    TargetMastigocladus laminosus

    Component of the cytochrome b6-f complex, which mediates electron transfer between photosystem II (PSII) and photosystem I (PSI), cyclic electron flow around PSI, and state transitions.

    Polypeptides: Cytochrome b6-f complex subunit 4Synonyms: Cytochrome b6-f complex subunit IV
  9. Target

    Propionyl-CoA carboxylase complex B subunit

    go.drugbank.com/bio_entities/BE0002846
    TargetStreptomyces coelicolor

    Polypeptides: Propionyl-CoA carboxylase complex B subunit
  10. Target

    Trafficking protein particle complex subunit 3

    go.drugbank.com/bio_entities/BE0003181
    TargetHumans

    May play a role in vesicular transport from endoplasmic reticulum to Golgi

    Polypeptides: Trafficking protein particle complex subunit 3